Abbreviation · Medical
AGP
Autogynephilia — a paraphilia, not a gender identity.
3 min read · updated May 2026
AGP is a paraphilia: a sexual deviation in which a man becomes sexually aroused by the thought of or the image of himself as a woman. The term was introduced in 1989 by the Canadian sexologist Ray Blanchard, based on clinical research at the Clarke Institute in Toronto. Blanchard explicitly distinguished AGP from gender identity: it is a sexual orientation toward one’s own imagined femininity.
AGP is often confused with or deliberately presented as “transgender identity”—which, according to Blanchard’s typology, it is precisely not. The other category in his typology is HSTS (Homosexual Transsexual): biological men who feel like women based on homosexual attraction to men, not on sexual arousal toward themselves.
Critical Analysis
Trans activism has largely banished AGP from public debate because the term reveals that a portion of MTF transitions do not stem from “feeling like a woman” but from a sexual paraphilia. Researchers such as Anne Lawrence (herself an autogynephile and trans woman) and J. Michael Bailey have empirically confirmed AGP in multiple studies. The difference between identity and paraphilia is fundamentally medical and ethical: you do not treat a paraphilia by adapting the body to the fantasy.
Political function of the acronym
An acronym like AGP is not a linguistic invention but a political instrument. Those who use the acronym simultaneously signal their acceptance of the associated ideological framework: identity takes precedence over biology, self-declaration over diagnosis, language over reality. Those who refuse to go along with it are accused of being outdated or hateful.
Resistance to this pressure does not come solely from conservative quarters. Lesbian organizations, sports associations, women’s rights groups, and clinicians are voicing opposition to the blurring of category boundaries. The acronym itself is often defended on the grounds of inclusion, but in practice it forces the abandonment of categories that actually serve a protective function—for women, for lesbians, for children.
Medical Context and the Evidence
The medical side of the debate has completely shifted in just a few years. The Cass Review (2024) found that the evidence base for puberty blockers and cross-sex hormones in minors is weak. Based on this, NHS England ceased routine prescribing. SBU (Sweden, 2022), COHERE (Finland, 2020), UKOM (Norway, 2023), and NICE (UK, 2020) reached the same conclusion.
In the communications of organizations that embrace AGP and related terms, these reevaluations are almost always absent. The image of settled science is maintained by remaining silent about the Cass Review and the Scandinavian shift. The WPATH Files (2024) showed that even among WPATH clinicians, there is uncertainty regarding informed consent for minors.
Implications for the public debate
Expanding acronyms is not without cost. Every new letter comes with a claim to recognition in legislation, education, and healthcare. Without evidence for the underlying category, policy is pursued as if the evidence were there. Those who ask questions receive no substantive answer but moral condemnation.
Language drives policy. Those who accept the acronym implicitly accept the claim that all identities it encompasses are equal and scientifically grounded. That is a political claim, not a linguistic one. Criticism of an acronym is not criticism of individuals—it is criticism of a framework that is increasingly being placed beyond the reach of debate.
International Reconsideration
In recent years, various national health authorities have distanced themselves from the gender-affirming model for minors. The common denominator: the evidence for lasting benefits is lacking, while the risks are real.
Cass Review (2024). Review commissioned by NHS England, conducted by Hilary Cass. Conclusion: the evidence base for puberty blockers and cross-sex hormones in minors is weak. NHS England ceased routine prescribing of puberty blockers outside of clinical trials.
SBU — Sweden (2022). The Swedish Agency for Health Technology Assessment (SBU) and Karolinska University Hospital discontinued the use of puberty blockers and hormones for minors outside of clinical trials. Reason: lack of evidence for effectiveness and safety.
NICE — United Kingdom (2020). Two NICE evidence reviews (puberty blockers and cross-sex hormones) classified the evidence base as very low certainty. None of the studies identified met modern methodological standards.
COHERE — Finland (2020). The Finnish Council for Choices in Health Care revised the protocol: psychotherapy as first-line treatment, medical transition for minors only in exceptional cases and within a research setting.
UKOM — Norway (2023). The Norwegian UKOM classified transgender care for minors as experimental; existing protocols do not meet the requirements for evidence-based care.
WPATH Files (2024). Internal discussions among WPATH clinicians acknowledge that informed consent with minors is problematic and that serious side effects (bone density, fertility, cognitive development) are not adequately explained.